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surgical resection followed by FHSRT and 83 with FHSRT 
only. Most frequent histology of primary site was lung 
cancer in 62.72% of patients and breast cancer in 13.63%. 
Planning CT scans were performed with patient in supine 
position using high precision head mask-fixation system. 
Gross tumor volume (GTV) was defined using the planning 
CT scan registered with the diagnostic MRI. A 3 mm 
expansion was given to the GTV for defining the planning 
target volume (PTV). Treatments were performed using 
dynamic conformal arches (VMAT) with 6 MV energy 
photons. Dose prescribed was 27 Gy in 3 fractions for 67 
treatments. Other dose schemes were: 24 Gy in 3 fractions 
for 20 treatments; 30 Gy in 10 fractions for 8 treatments; 
35 Gy in 5 fractions for 7 treatments, 30 Gy in 5 fractions 
for 7 treatments and 30 Gy in 3 fractions for 1 treatment. 
Kaplan-Meier actuarial method was used for the analysis 
of the overall survival, disease free survival and the 
correlation of the dose scheme and time to progression.  
Results 
Local progression was observed in 54 of the 110 
treatments, among these, there were 26 patients who had 
one single lesion and 28 who had 2 or more lesions. In the 
local progression group, 42 patients receive further 
treatment. Twenty-two receive re-irradiation using 
FHSRT, 13 with WBRT, 5 where treated with SRS and 2 with 
surgical resection. Twelve patients did not receive any 
further treatment. Median overall survival was 8.36 
months (r: 1-45). The median disease free survival was 6.7 
months (r: 1-43). Grade 2 toxicity (CTCAE v4) was 
observed in 3 patients, and 10 patients presented 
neurological symptoms during FHSRT. Radiation necrosis 
was confirmed in 3 patients, 2 by RMI and 1 with coline 
PET-TC. When analyzing by subgroups the different dose 
schemes used, no statistically significant differences were 
found with respect to the time of recurrence. 
Conclusion 
FHSRT is an effective alternative treatment for non-
multiple brain metastases with high local control and 
acceptable tolerance. There were no differences 
regarding the prescribed doses and the time to 
progression. More data is needed in order to establish the 
optimal fractionation and dose scheme to be used. 
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Purpose or Objective 
Patients with brain metastases (BM) represent an 
extremely diverse group with substantial variability in risk 
of intra-cranial failure and survival. Patient selection for 
stereotactic radiotherapy (SRT) alone is complex and 
requires considering multiple predictive factors. Given 
that the ultimate goal of SRT is to prolong survival without 
whole brain radiotherapy (WBRT), a nomogram based on 
multi-institutional data was developed by another team to 
display 6 and 12 months WBRT-free survival (WBFS) 
probabilities (Gorovets, al.  IJROBP 2018). The aim of this 
study was to externally validate this nomogram. 
Material and Methods 
We retrospectively reviewed the data of 70 patients 
treated between 2008-2017 by SRT for resected BM. The 
primary endpoint was the WBFS. Two subgroups of 35 
patients were constructed with respect to the patient 
score in the nomogram (superior and inferior to the 
median). In each group, the observed WBFS was plotted 
against the predicted WBFS. The ROC curve and AUC were 
calculated for both 6 and 12 months time points. 
Results 
After a median follow up of 16.8 months, the 1-year local 
and distant brain failure rates were 14.3% and 35.0 %, 
respectively. The median time to salvage WBRT was 9.6 
months. Median time to the first intracranial failure was 
7.7 months. At the time of first recurrence, 90 % received 
local salvage therapy. We performed repeated SRT for 34% 
and salvage WBRT in 56%. After median time of 8.5 
months, 10 patients experienced a second intracranial 
failure. Eight of 10 patients received further salvage 
therapy (5 WBRT, 3 SRT). The WBFS rates at 6 and 12 
months were 87 % [IC 95% = 79-95 %] and 56 % [IC 95% = 45-
69%] , respectively. In terms of calibration, the 6 months 
rates were overestimated while they were accurate at 12 
months (Fig. 1). It is reflected by the evolution of the 
cumulative proportion of WBRT or death in both subgroups 
with observed rates inferior to expectations at 6 months 
while they superimpose at 12 months (Fig. 2). A ROC curve 
was plotted for the 6 and 12 months nomogram 







In our population of patients with operated BM and then 
stereotactically irradiated, the nomogram predicted 
correctly the WBFS at 12 months but not at 6 months. The 
median time to salvage WBRT was 9.6 months in our series 
while it was 6.2 months in the series by Gorovets. The fact 
that one third of our patients were treated with SRT as 
first salvage treatment may have played a role. Patients 
were operated and this may also be a confounding 
factor.  All in all, it reflects the inherent limitation of 
applying prediction models to highly heterogeneous 
populations. Including more patients and characteristics 
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(e.g. molecular data) may improve the concordance 
index. 
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Purpose or Objective 
Glioblastoma (GBM) is a highly aggressive malignant brain 
tumour with a median overall survival of only 15 months. 
After postoperative chemoradiotherapy, most recurrences 
occur within or at the margin of the treatment volume. 
The standard clinical target volume (CTV) is typically 
defined as an isotropic 2 cm expansion around the surgical 
cavity and the area of contrast enhancement. This 
isotropic margin is not taking into account the preferential 
tumour growth along the white matter tracts of the brain. 
Diffusion tensor imaging (DTI) MRI can be used to model 
white matter tracts. The aim of this phase 1 feasibility 
study is to evaluate DTI-MRI diffusion growth models in the 
biological CTV definition of GBM. 
Material and Methods 
Adult GBM patients referred for postoperative RT were 
included, and underwent an additional pre-treatment DTI-
MRI; actual treatment wasn’t altered. The standard CTV 
was defined as described above, respecting anatomical 
barriers. DTI-MRI was used to create two biological CTVs, 
iso-volumetric to the standard CTV, using anisotropic 
margins based on tensor directionality of γ0 (bCTVγ0) and 
γ20 (bCTVγ20; higher γ meaning a higher assumed 
probability of tumour spread along white matter tracts). 
The similarity of the CTV and the bCTVs was assessed using 
the Dice similarity score (DSC; 0=no overlap, 1=complete 
overlap). Treatment effect was assessed by 3-monthly MRI 
and described by RANO criteria. Progression was defined 
as central, in-field/marginal and distant with respective 
≥95%, 20-95%, or <20% of the recurrence volume (RV) 
located within the D95%. Only patients with an in-
field/marginal or distant recurrence were selected for 
comparison of the bCTVs to the RV. The overlap or minimal 
distance between the bCTVs and the delineated RV was 
calculated. 
Results 
Between 10/2016 and 06/2018 38 patients were included. 
One patient went off-study and one was lost to follow-up, 
leaving 36 for analyses. Gross total resection was 
performed in 42% of patients, and 89% completed 
irradiation to 60 Gy in 30 fractions (Table). At a median 
follow-up of 9.5 (range 3-21) months, 23 patients had 
disease progression; 2 clinical, 19 central, 1 in-
field/marginal, 2 distant. The median PFS was 7.0 (range 
4.5-9.5) months. The mean DSC between CTV and bCTVγ0 
was 0.75 (range 0.65-0.85), and CTV and bCTVγ20 was 
0.72 (range 0.62-0.81) (bCTVγ0 vs bCTVγ20 p<0.001). For 
patient 1 with a non-central recurrence the 
CTV/bCTVγ0/bCTVγ20 overlapped with the RV by 
87/90/89% (Figure). For patient 2 the 
CTV/bCTVγ0/bCTVγ20 overlapped with the RV by 
19/21/25%. 
For patient 3 (no overlap) the shortest distance from the 







Biological DTI-MRI based CTV showed marginal 
improvement in a limited number of GBM patients with 
non-central recurrence. Further investigation in a larger 
cohort including non- iso-volumetric approaches is needed 
for further improvement in CTV definition. 
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